MedTrace Logo

Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs.

NCT06046534 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2025-05-13

No results posted yet for this study

Summary

The ERYTHRO study is a retrospective medical chart review study of patients in the AMANA and ATUc Early Access Programs (EAPs) across a number of countries, to assess anifrolumab usage and patient experience in treating SLE in a real-world setting. Since patient safety data are already collected and reported according to regulatory requirements through EAPs, this study will not collect safety data.

Conditions

Interventions

OTHER

None (Observational study)

Not applicable since this is observational study.

Sponsors & Collaborators

  • CernerEnviza / Oracle

    collaborator UNKNOWN

  • AstraZeneca

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-27
Primary Completion
2024-06-10
Completion
2024-06-10

Countries

  • France
  • Greece
  • Israel
  • Italy
  • Portugal
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06046534 on ClinicalTrials.gov